Early research (Phase 1)Ended earlyNCT02890381
What this trial is testing
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
Who this might be right for
Respiratory Syncytial Virus Infections
National Institute of Allergy and Infectious Diseases (NIAID) 17